Wesfarmers – Buy

Posted on | by Leon Hinde

Wesfarmers is under Algo Engine buy conditions and is a current holding in our model portfolio.

Wesfarmers now holds 19.3% of Australian Pharmaceutical Industries. The acquisition has less than two weeks left in confirmatory due diligence. The battle between Sigma and Wesfarmers for the API business and final offers will be worth watching.

Accumulate.

TWE – FY22 Earnings

Posted on | by Leon Hinde

Treasury Wine Estates is under Algo Engine buy conditions.

TWE continues to adjust to a post pandemic/post Chinese tariff environment. FY21 EBIT of $510 exceeded market expectations. After a number of years of disappointment for TWE in this region, we see America’s division accelerating growth into FY22.

FY22 EBIT growth is forecast to be in the mid to high single-digit range.

Neuren – Buy Signal

Posted on | by Leon Hinde

Neuren Pharmaceuticals is under Algo Engine buy conditions.

Neuren Pharmaceuticals reported the successful completion of its Share Purchase Plan (SPP) at $2.05 per share, which closed on Friday 1 October 2021. The SPP was offered to give all shareholders in Australia and New Zealand the opportunity to subscribe for additional shares at the same price as was offered to institutional and sophisticated investors in the recent placement.

Total gross proceeds of $23.3 million from the placement and SPP will accelerate the development and increase the value of NNZ-2591 for four neurodevelopmental disorders, by enabling a Phase 2 clinical trial in Prader-Willi syndrome and the foundational work for Phase 3 development across Prader-Willi, Phelan-McDermid, Angelman and Pitt Hopkins syndromes. NNZ-2591 has Orphan Drug designation from the US Food and Drug Administration for all four disorders and from the European Medicines Agency for three.

Neuren CEO Jon Pilcher commented: “We are pleased with and grateful for the support of shareholders in both the placement and the SPP. Neuren is now in a strong financial position as we approach the Rett syndrome Phase 3 results for trofinetide and advance the development of NNZ-2591 for multiple neurodevelopmental disorders in parallel.”